(Press-News.org) HOUSTON and DUBLIN ― The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz’s investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
The collaboration will combine MD Anderson’s translational medicine and clinical research expertise with Jazz’s expanding oncology drug development capabilities to investigate the potential of zanidatamab as monotherapy and in combination with other treatments for patients with different tumor types and stages. This includes its possible applicability in early-stage breast cancer, treatment areas where other HER2-directed therapies have failed, cancers with varying degrees of HER2-expression, and potentially rare, tissue-agnostic cancers.
"Current data indicates that zanidatamab has anti-tumor activity in multiple HER2-positive solid tumors, including positive results from a pivotal clinical trial for patients with HER2-amplified biliary tract cancers,” said Funda Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics at MD Anderson. “We are pleased to extend our research efforts with Jazz through this new collaboration, which aims to address significant unmet needs in HER2-expressing solid tumors and to look for safe and effective alternatives to chemotherapy in diseases like early-stage breast cancer."
MD Anderson has been instrumental in researching breakthrough cancer therapies and was a key contributor to early investigations exploring the use of zanidatamab against an actionable target in the treatment of multiple tumor types and the subsequent Phase II HERIZON-BTC-01 trial, which evaluated zanidatamab for patients with treatment-refractory HER2-amplified biliary tract cancers. Results presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and a confirmed objective response rate of 41%. The presentation was selected for the 2023 Best of ASCO® program.
Jazz and MD Anderson will establish a joint steering committee to oversee the collaboration, which will fund multiple studies over its five-year term. Research under the collaboration is expected to begin in late 2023 or early 2024. This effort builds upon a previous strategic collaboration between Jazz and MD Anderson focused on hematologic malignancies.
"We think zanidatamab has best-in-class potential as a bispecific antibody utilizing biparatopic binding, which results in HER2 signal blockade, as well as immune-mediated cytotoxicity of HER2-expressing cancer cells. Zanidatamab has compelling anti-tumor activity across a broad range of HER2-positive cancers," said Rob Iannone, M.D., executive vice president, global head of research and development at Jazz Pharmaceuticals. "We look forward to continuing to collaborate with MD Anderson to further evaluate zanidatamab’s potential to be transformative to the current standard of care in multiple HER2-expressing cancers. We are dedicated to advancing new treatment options for patients and we believe in the power of collaboration to accelerate the pace of research in difficult-to-treat cancers where persistent treatment gaps remain.”
Read this press release in the MD Anderson Newsroom.
-30-
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit JazzPharmaceuticals.com for more information.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
END
MD Anderson and Jazz Pharmaceuticals announce five-year collaboration to evaluate zanidatamab in HER2-expressing cancers
2023-11-07
ELSE PRESS RELEASES FROM THIS DATE:
An ammonia trail to exoplanets
2023-11-07
They reveal the origin of wine, the age of bones and fossils, and they serve as diagnostic tools in medicine. Isotopes and isotopologues – molecules that differ only in the composition of their isotopes – also play an increasingly important role in astronomy. For example, the ratio of carbon-12 (12C) to carbon-13 (13C) isotopes in the atmosphere of an exoplanet allows scientists to infer the distance at which the exoplanet orbits its central star.
Until now, 12C and 13C bound in carbon monoxide were the only isotopologues that could be measured in the atmosphere of an exoplanet. Now a team of researchers has succeeded in detecting ammonia isotopologues ...
Online shopping for tobacco products rises with California flavor restrictions
2023-11-07
Online shopping for cigarettes and vaping products increased significantly in the weeks following the implementation of SB-793, a 2022 California law prohibiting the sale of flavored tobacco products. Researchers at the Herbert Wertheim School of Public Health and Human Longevity Science at University of California San Diego identified potential loopholes in tobacco control policies due to the absence of explicit regulations on e-commerce sales in retailer licensing programs.
Reporting in the journal Tobacco Control on Nov. 7, 2023, researchers assessed the ...
UTSA researchers discover new method to inhibit cholera infection
2023-11-07
Karl Klose, director of The South Texas Center for Emerging Infectious Diseases (STCEID) and the Robert J. Kleberg, Jr. and Helen C. Kleberg College of Sciences Endowed Professor, coauthored a research article with Cameron Lloyd ’23, a UTSA doctoral student who graduated in August with a Ph.D. in molecular microbiology and immunology under the guidance of Klose.
The research paper investigates a novel strategy for inhibiting the spread and infection of Vibrio cholerae, the bacteria responsible for the disease, cholera.
The research article is entitled, “A peptide-binding ...
The molecular basis of ventilator-induced diaphragm weakness
2023-11-07
A study presents evidence that mitochondrial fragmentation is a proximal mechanism underlying ventilator-induced diaphragm dysfunction (VIDD)—and identifies a possible therapeutic to limit diaphragm atrophy during a stay in intensive care. Previous research has established that many of the cellular pathways responsible for VIDD are kicked off by oxidative stress stemming from diaphragm inactivity. Stefan Matecki and colleagues studied the molecular causes of this oxidative stress in mice. Just six hours on mechanical ventilation was enough to increase expression of dynamin-related protein 1 (DRP1), which is involved in mitochondrial ...
Bisphenol A and asthma in mice
2023-11-07
The “hygiene hypothesis” posits that allergic asthma can be triggered by a childhood environment that is too clean and sterile. One studied mechanism underlying this relationship is the influence of microbial lipopolysaccharides (LPS), which train the immune system. In the absence of LPS, Toll-like receptors in the human body will become more sensitive, which can lead to an exaggerated allergic response to triggers such as house dust mites. Mingliang Fang and colleagues explored how the environmental pollutant bisphenol ...
Mountain goats seek snow to shake off insects
2023-11-07
Losing summer snow patches may hit mountain goats hard, according to a study that suggests that goats seek out snow to avoid biting insects. Many cold-adapted species take advantage of patches of snow that linger through the summer, as corridors for travel, sources of drinking water, zones for cooling off, or places to play. As the climate changes, many species will have reduced access to snow patches. Forest Hayes and Joel Berger explored what this lack of summer snow might mean for mountain goats (Oreamnos americanus) in Glacier National Park, which has lost 85% of its glaciers since 1850. The team studied goats in the park—along with another population 1,000 ...
Mapping the landscape: Amsterdam UMC receives millions to lead European research into obesity
2023-11-07
Obesity is a growing health problem that disproportionately affects people and communities with a low socio-economic position in Europe. Thanks to a Horizon grant worth more than 10 million euros, Jeroen Lakerveld, epidemiologist at Amsterdam UMC, is now set to lead a European consortium in better identifying the causes of obesity and designing guidelines to tackle the problem.
"Social and cultural factors play a role in our lifestyle behaviours but so do our genes and the environment in which we live and work. Residents of neighbourhoods are not equally exposed to unhealthy factors: ...
Guilt not as persuasive if directly tied to personal responsibility
2023-11-07
PULLMAN, Wash. – Invoking a sense of guilt—a common tool used by advertisers, fundraisers and overbearing parents everywhere—can backfire if it explicitly holds a person responsible for another’s suffering, a meta-analysis of studies revealed.
While guilt is widely used to try and persuade people to act, research has been mixed on its effectiveness in spurring behavior change. This analysis, published in the journal Frontiers in Psychology, found that overall guilt had only a small persuasive effect, which is in line with previous research.
However, researchers uncovered that guilt worked better ...
Previous genetic association studies involving people with European ancestry may be inaccurate
2023-11-07
Researchers have found that previous studies analyzing the genomes of people with European ancestry may have reported inaccurate results by not fully accounting for population structure. By considering mixed genetic lineages, researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, demonstrated that previously inferred links between a genomic variant that helps digest lactose and traits such as a person’s height and cholesterol level may not be valid.
The study, published in Nature Communications, shows that people with European ancestry, who were previously treated as a genetically homogenous group in large-scale genetic ...
Contraceptive pills might impair fear-regulating regions in women’s brains
2023-11-07
More than 150 million women worldwide use oral contraceptives. Combined OCs (COCs), made up of synthetic hormones, are the most common type. Sex hormones are known to modulate the brain network involved in fear processes.
Now a team of researchers in Canada has investigated current and lasting effects of COC use, as well as the role of body-produced and synthetic sex hormones on fear-related brain regions, the neural circuitry via which fear is processed in the brain.
“In our study, we show that healthy women currently using COCs had a thinner ventromedial prefrontal cortex than men,” said Alexandra Brouillard, ...